Similarly, the phase 3 CheckMate-648 trial (NCT03143153) led to the approval of both nivolumab + CT and nivolumab + ipilimumab in the US for patients whose tumors express PD-L1 (≥1), whereas in the EU, these regimens are restricted for use in patients with a tumor proportion score (TPS) ≥1% (18, 19). This evidence concerns the gene CD274 and neoplasm.